The biomarker prevalence data your strategy actually needs
NeoGenomics Real-World Insights turns source data into prevalence, testing trends, and concordance insights that drive clinical strategy, publication planning, and payer evidence. NeoGenomics data is grounded in what’s actually happening in community oncology settings, not what’s inferred from claims.
NeoGenomics Real-World Insights draws from our multimodal clinicogenomic database of structured, de-identified, first-party lab data across five testing modalities.
NGS panel results, mutation status, gene fusions, copy number variants —all from the lab that generated them.
IHC results across 335 IHC markers including PD-L1, HER2, CLDN18.2, FOLR1, and emerging biomarkers, with clone, score, expression levels, and indication with source digital pathology images.
Ordering volume over time, single-gene vs. NGS adoption rates, guideline-to-practice gaps by setting and region.
Understand the biomarker-eligible population in your target indication before launch, by territory, practice setting, and HCP, with data that reflects community oncology, not trial populations.
Real-world biomarker prevalence and testing pattern data is the foundation of high-impact publications. Our data has supported manuscripts across ASCO, ASH, and peer-reviewed journals.
Lab-confirmed molecular data, not claims proxies, gives payer submissions a defensible foundation for population sizing, testing rate analysis, and economic burden modeling.
Our data shows what's actually ordered in the community vs. what NCCN recommends — the gap is where Medical Affairs education programs create the most impact.
